Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...

For example, Pfizer (NYSE: PFE) launched its RSV vaccine, Abrysvo, in 2023. It's currently approved to prevent infections for ...

"This particular vaccine … is an effective way of protecting older adults against serious infection that can be caused by RSV." He's encouraged by the expansion of eligibility in Alberta ...

Patients' confidence in vaccines has waned since the COVID pandemic, according to a national poll and doctors.

We survived the nightmare of watching our son battle RSV in the pediatric ICU. It never occurred to us that we'd later have to worry about measles with our daughter.

RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...

Presentation Details Title: Safety and Immunogenicity of PIV5-Vectored RSV Intranasal Vaccine (BLB201) in Healthy Adults and Children Date/Time: March 13, 2025 / 8:30 am to 8:45 am (GMT-3 ...

The incident occurred months after health authorities discovered the GP’s clinic had incorrectly stored vaccines, potentially ...

BLB201 is an RSV vaccine candidate that is currently in Phase ... the prevention of RSV-associated acute respiratory disease in adults (>60 years) and pediatric populations (<2 years).